Patent Docket No. P1795R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Wyne P. Lee et al. Serial No.: 09/738,540 Filed: 14 December 2000 For: TREATMENT METHOD	Group Art Unit: 1644 Examiner: M. Haddad CERTIFICATE OF TRANSMISSION I hereby certify that this correspondence is being facsimile transmitted to U.S. Patent and Trademark Office fax no. (703)308-4315 on May 8, 2002 Janet Tse

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT UNDER 37 C.F.R §1.111

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This paper is responsive to the Communication mailed February 8, 2002, setting forth the Examiner's restriction requirement in connection with the above-identified application. A response to the restriction requirement was initially due on March 8, 2002. Enclosed is a Petition for a two (2) month Extension of Time to extend the due date for this response from March 8, 2002 to May 8, 2002, along with the requisite fee under 37 CFR §1.17(c). Accordingly, this response is timely filed.

Reconsideration is respectfully requested in view of the amendments and remarks submitted herein.

RESTRICTION REQUIREMENT

Claims 1-16 were pending. The Examiner has required restriction of the claims to one of the following groups under 35 U.S.C. §121:

I. Claims 1-9, drawn to a method of treating a TNF-α or LFA-1 mediated disorder such as autoimmune pathologies comprising administering an anti-LFA-1 antibody and TNFα binding fusion protein, classified in Class 424, subclass130.1 and 178.1.

II Claims 1-9, drawn to a method of treating a TNF-α or LFA-1 mediated disorder such as infectious diseases comprising administering an anti-LFA-1 antibody and TNFα binding fusion protein, classified in Class 424, subclass 130.1 and 178.1

III. Claims 1-9, drawn to a method of treating a TNF-α mediated disorder such as inflammatory disease comprising administering an anti-LFA-1 antibody and TNFα binding fusion protein, classified in class 424, subclass 130.1 and 178.1.

IV. Claims 1-9, drawn to a method of treating a TNF-α mediated disorder such as neurodegenerative diseases comprising administering an anti-LFA-1 antibody and TNFα binding fusion protein, classified in Class 424, subclass 130.1 and 178.1.

V. Claims 1-9, drawn to a method of treating an LFA-1 mediated disorder such as cancer comprising administering an anti-LFA-1 antibody and TNFα binding fusion protein, classified in Class 424, subclass 130.1 and 178.1.

VI. Claims 1-9, drawn to a method of treating an LFA-1 mediated disorder such as organ transplantations comprising administering an anti-LFA-1 antibody and TNFα binding fusion protein, classified in Class 424, subclass 130.1 and 178.1.

VII. Claims 10-16, drawn to composition, comprising an anti-CD11a antibody and a TNFα fusion protein, classified in Class 514, subclass 8.

In response to the restriction requirement, Applicants hereby elect, without traverse, the invention of Group I claims for further prosecution. Applicants expressly reserve the right under 35 U.S.C. §121 to file one or more divisional applications directed to the non-elected subject matter during the pendency of the instant application.

SPECIES ELECTION

The Examiner has required election of one of the following species of antibodies wherein the antibody is against.

A) CD11a,

B) CD18, or

C) both CD11a and CD18.

In addition, within the claimed Invention I, the Examiner has required election of one of the following species of autoimmune pathology:

A) systemic lupus erythematosus and rheumatoid arthritis;

B) thyroidosis;

C) graft versus host disease;

D) scleroderma

E) diabetes mellitus;